Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7059.

https://doi.org/10.1182/blood-2024-201563

Published: 2024

Journal Articles

Natural history study of patients with familial platelet disorder with associated myeloid malignancy

Blood (2023) 142 (25): 2146–2158.

https://doi.org/10.1182/blood.2023019746

Published: 2023

Includes: Supplemental data

Journal Articles

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

Blood (2023) 142 (Supplement 1): 337.

https://doi.org/10.1182/blood-2023-181811

Published: 2023

Journal Articles

Clonal Bone Marrow Plasma Cells Are Common in Patients with Vexas Syndrome

Alina Dulau-Florea, Raul C. Braylan, Yanna Ding, Nisha Patel, Katherine Calvo, Elizabeth Hill, Emma M. Groarke, Neal S. Young, Bhavisha A. Patel

Blood (2023) 142 (Supplement 1): 4681.

https://doi.org/10.1182/blood-2023-186736

Published: 2023

Journal Articles

Bone Marrow, Laboratory, and Clinical Features in Pediatric Patients with RUNX1 Familial Platelet Disorder with Associated Myeloid Malignancy (FPDMM)

Seila De Leon, Michelly Sampaio De Melo, Nisha Patel, Alina Dulau Florea, Irina Maric, Raul C. Braylan, Weixin Wang, Matthew Merguerian, Elizabeth J. Andrews, Lea Cunningham, David J. Young, Shawn Chong, Natalie Deuitch, Joie Davis, Kathleen Craft, Theo Heller, Pamela Frischmeyer-Guerrerio, Paul Pu Liu, Katherine R. Calvo

Blood (2023) 142 (Supplement 1): 4109.

https://doi.org/10.1182/blood-2023-187600

Published: 2023

Journal Articles

A rare case of well-differentiated systemic mastocytosis

Nisha Patel, Irina Maric

Blood (2023) 141 (19): 2403.

https://doi.org/10.1182/blood.2022019281

Published: 2023

Journal Articles

Transient Responses and Significant Toxicities Due to Cytopenias and Rashes with Anti-CD30 CAR T Cells for CD30-Expressing Lymphomas: Results of a Phase I Clinical Trial

Jennifer N. Brudno, Jeremiah Karrs, Danielle Natrakul, Nisha Patel, Lekha Mikkilineni, Jennifer Mann, David F. Stroncek, Steven Highfill, Norris Lam, Genevieve C. Fromm, Rashmika Patel, Stefania Pittaluga, James N. Kochenderfer

Blood (2022) 140 (Supplement 1): 12731–12732.

https://doi.org/10.1182/blood-2022-157149

Published: 2022

Journal Articles

ABO Blood Type and Outcomes in a Diverse COVID-19 Infected Population

Sonal Paul, MD, Nisha Patel, MD, Chathula Kumarasinghe, MD, Neil Nimkar, MD, Angelica Singh, MD, Nivetha Vishnuvardhan, MD, Farah Ashraf, MD, Anita Mazloom, MD, Rich Kodama, MD, Amardeep Kalsi, MD, Soeb Usta, MD, Abeer Ashfaq, MD, Peter Gregos, MD, Uqba Khan, MD, Jeremy Weingarten, MD, Eshan Patel, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-142943

Published: 2020

Journal Articles

COVID-19 Prognostic Score Utilizing Hematological and Inflammatory Markers to Determine Outcomes of Hospitalized Patients

Amardeep Kalsi, MD, Sana Irfan Khan, MD, Asad Rehman, Neil Nimkar, MD, Angelica Singh, MD, Nivetha Vishnuvardhan, MD, Sonal Paul, MD, Farah Ashraf, DO, Anita Mazloom, MD, Nisha Patel, MD, Rich Kodama, MD, Abeer Ashfaq, MD, Chathula Kumarasinghe, MD, Soeb Usta, MD, Peter Gregos, MD, Eshan Patel, MD, Uqba Khan, MD

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-142971

Published: 2020

Journal Articles

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Blood (2020) 136 (Supplement 1): 43–45.

https://doi.org/10.1182/blood-2020-136148

Published: 2020

Journal Articles

Evaluation of Antiplatelet and Anticoagulation Therapy in High-Risk COVID-19 Patients

Farah Ashraf, DO, Anita Mazloom, MD, Neil Nimkar, MD, Nisha Patel, MD, Amardeep Kalsi, MD, Angelica Singh, MD, Sonal Paul, MD, Nivetha Vishnuvardhan, MD, Abeer Ashfaq, MD, Soeb Usta, MD, Rich Kodama, MD, Chathula Kumarasinghe, MD, Peter Gregos, MD, Jeremy Weingarten, MD, Uqba Khan, MD, Eshan Patel, MD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-137282

Published: 2020

Journal Articles

Outcomes in COVID-19 Patients on Treatment Dose Anti-Coagulation Compared to Prophylactic Dose Anti-Coagulation

Rich Kodama, MD, Amardeep Kalsi, MD, Angelica Singh, MD, Nivetha Vishnuvardhan, MD, Neil Nimkar, MD, Sonal Paul, MD, Soeb Usta, MD, Farah Ashraf, MD, Anita Mazloom, MD, Abeer Ashfaq, MD, Nisha Patel, MD, Chathula Kumarasinghe, MD, Uqba Khan, MD, Peter Gregos, MD, Jeremy Weingarten, MD, Eshan Patel, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-142552

Published: 2020

Journal Articles

Interactome of Aiolos/Ikaros in Diffuse Large B-Cell Lymphoma (DLBCL) Reveals Novel Combination of Cereblon Modulators (CELMoD) and Histone Deacetylase (HDAC) Inhibitors

Patrick R. Hagner, PhD, Hsiling Chiu, MS, Vivek S. Chopra, PhD, Martino S. Colombo, PhD, Nisha Patel, PhD, Maria Ortiz, Remco S. Loos, PhD, Fadi Towfic, PhD, Michelle Waldman, MS, Anita K Gandhi

Blood (2019) 134 (Supplement_1): 306.

https://doi.org/10.1182/blood-2019-126681

Published: 2019

NARROW

A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Natural history study of patients with familial platelet disorder with associated myeloid malignancy

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

Clonal Bone Marrow Plasma Cells Are Common in Patients with Vexas Syndrome

Bone Marrow, Laboratory, and Clinical Features in Pediatric Patients with RUNX1 Familial Platelet Disorder with Associated Myeloid Malignancy (FPDMM)

A rare case of well-differentiated systemic mastocytosis

Transient Responses and Significant Toxicities Due to Cytopenias and Rashes with Anti-CD30 CAR T Cells for CD30-Expressing Lymphomas: Results of a Phase I Clinical Trial

ABO Blood Type and Outcomes in a Diverse COVID-19 Infected Population

COVID-19 Prognostic Score Utilizing Hematological and Inflammatory Markers to Determine Outcomes of Hospitalized Patients

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Evaluation of Antiplatelet and Anticoagulation Therapy in High-Risk COVID-19 Patients

Outcomes in COVID-19 Patients on Treatment Dose Anti-Coagulation Compared to Prophylactic Dose Anti-Coagulation

Interactome of Aiolos/Ikaros in Diffuse Large B-Cell Lymphoma (DLBCL) Reveals Novel Combination of Cereblon Modulators (CELMoD) and Histone Deacetylase (HDAC) Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only